Advertisement

Topics

Alexion Antibody Technologies, Inc. Company Profile

06:14 EST 10th December 2018 | BioPortfolio

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting severe unmet medical needs including cancer, autoimmune disorders, and inflammation. AAT was formed in September 2000 from the merger of the discovery platform of Prolifaron, Inc. with the established antibody development capacity of Alexion Pharmaceuticals, forming a powerhouse in antibody discovery and development. Alexion is approaching full integration, from discovery through commercialization.

Location

3985 Sorrento Valley Blvd Ste, A
San Diego
California
92121
United States of America

Contact

Phone: (858) 550-3490
Fax: (858) 550-3498
Email: kpolany@alxnsd.com


News Articles [863 Associated News Articles listed on BioPortfolio]

Alexion to Acquire Syntimmune for up to $1.2 Billion

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune today announced that they have entered into a definitive agreement for Alexion to acquire Syntimmune, a c...

Alexion to Obtain Syntimmune for $400M up Front

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neo...

Alexion continues rare disease M&A with Syntimmune acquisition

Alexion has agreed to pay up to $1.2bn for Syntimmune and its lead asset SNT001, a monoclonal antibody designed to treat warm autoimmune haemolytic anaemia.

Alexion buys Syntimmune for $400mm plus earn-outs

Alexion Pharmaceuticals Inc. will pay $400mm up front to acquire privately held antibody therapeutics developer Syntimmune Inc. The deal also includes up to $800mm in milestone-dependent earn-outs. ...

Alexion wraps up $1.2bn acquisition of Syntimmune

The acquisition adds to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized monoclonal antibody that inhibits the interaction of neonatal Fc receptor (FcRn) with ...

M&As this week: Alexion Pharmaceutical, OvaScience

Alexion Pharmaceuticals has completed an acquisition of Syntimmune. Following the transaction, Syntimmune will add its clinical-stage drug candidate SYNT001 to Alexion’s...Read More... The post...

Alexion to buy Syntimmune for up to $1.2bn

US-based biopharmaceutical company Alexion has signed a definitive agreement to acquire biotechnology firm Syntimmune for up to $1.2bn. The terms...Read More... The post Alexion to buy Syntimmune for ...

Alexion Pharmaceuticals Turns Lower Despite Upbeat Q3 Earnings, Guidance

WASHINGTON (dpa-AFX) - After seeing initial strength, shares of Alexion Pharmaceuticals (ALXN) have moved sharply lower over the course of the trading session on Wednesday. Alexion is currently do...

PubMed Articles [1169 Associated PubMed Articles listed on BioPortfolio]

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.

The antibody drug market is rapidly expanding, and various antibody engineering technologies are being developed to create antibodies that can provide better benefit to patients. Although bispecific a...

In Vitro Selection of Single-Domain Antibody (VHH) Using cDNA Display.

Single-domain antibody (e.g., Nanobody, VHH antibody) is a promising scaffold for therapeutic and diagnostic reagents. To expand the range of target molecules, in vitro selection using cell-free displ...

Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.

Monoclonal antibodies are established treatment options in cancer therapy. However, not all patients benefit from antibody therapy. Basic research and findings from clinical trials revealed that certa...

Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-MAG antibody polyneuropathy.

Rituximab, a chimeric anti-CD20 monoclonal antibody (mAb), has been used in polyneuropathy associated with anti-MAG antibody polyneuropathy with controversial results. Herein, we report on two patient...

Antigen binding allosterically promotes Fc receptor recognition.

A key question in immunology is whether antigen recognition and Fc receptor (FcR) binding are allosterically linked. This question is also relevant for therapeutic antibody design. Antibody Fab and Fc...

Clinical Trials [2175 Associated Clinical Trials listed on BioPortfolio]

Application of Monitoring and Intervention Technologies in Suboptimal Health Status

The purpose of this study is to use monitoring and intervention technologies in suboptimal health status in a general population in China and evaluate the effectiveness of these technologi...

Wheeze Detection in Adults During Dynamic Bronchial Situations Measured by PulmoTrack® 2010 With WIM-PC™ Technologies Recording

The PulmoTrack® 2010 with WIM-PC™ Technologies device, indicated for acoustic pulmonary function measurement that quantifies the presence of wheezing. This study was designed in order t...

JCV Antibody Program (STRATIFY-1)

Study conducted to define the prevalence of Serum JC Antibody in relapsing MS patients receiving Tysabri or being considered for such treatment. Analytically validate the JCV antibody ass...

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

EBV positive tumor accounts for 8-9% of all gastric cancer (GC) patients. PD-1 antibody has been proved as third line therapy for PD-L1 positive gastric cancer. Previous studies showed tha...

Testing Latest Version of NidekRS3000Adv

The investigators would like to know if different imaging devices can improve the quality of images and visualization of imaged tissues. Also, the investigators would like to find out whet...

Companies [1712 Associated Companies listed on BioPortfolio]

Alexion Antibody Technologies, Inc.

Alexion Antibody Technologies, Inc. (AAT) is a wholly owned subsidiary of Alexion Pharmaceuticals [ALXN]. AAT is engaged in discovering and developing a portfolio of antibody therapeutics targeting se...

Alexion Pharmaceuticals Inc.

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare disorders. Alexion developed ...

Alexion Pharmaceuticals Incorporated

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rar...

Antibody Solutions Inc

Antibody Solutions Inc., based in Mountain View in the San Francisco Bay Area, offers quality antibody development, antibody manufacture and immunoassay development that are optimized for your specifi...

Takeda San Francisco Inc.

Takeda San Francisco was established in November 2007 and supports Takeda's therapeutic antibody research aiming to build antibody technology platforms based on technologies such as discovery and ...

More Information about "Alexion Antibody Technologies, Inc." on BioPortfolio

We have published hundreds of Alexion Antibody Technologies, Inc. news stories on BioPortfolio along with dozens of Alexion Antibody Technologies, Inc. Clinical Trials and PubMed Articles about Alexion Antibody Technologies, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alexion Antibody Technologies, Inc. Companies in our database. You can also find out about relevant Alexion Antibody Technologies, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Autoimmune Disorders
Autoimmune disorders are conditions that occurs when the immune system mistakenly attacks and destroys healthy body tissue. There are more than 80 different types of autoimmune disorders. Normally the immune system's white blood cells help protect ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...


Corporate Database Quicklinks



Searches Linking to this Company Record